Brief: Aptose Biosciences On Feb 29, Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard Transfer Of Listing From Nasdaq
01/03/2024 23:33
March 1 (Reuters) - Aptose Biosciences Inc APS.TO :
* APTOSE BIOSCIENCES :ON FEB 29, RECEIVED NOTICE OF
DELISTING OR
FAILURE TO SATISFY CONTINUED LISTING RULE OR STANDARD; TRANSFER
OF LISTING FROM NASDAQ
Further company coverage: APS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting